Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Summary

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.

Conditions

• Gastrinoma
• Glucagonoma
• Insulinoma
• Metastatic Gastrointestinal Carcinoid Tumor
• Metastatic Pheochromocytoma
• Pancreatic Polypeptide Tumor
• Recurrent Gastrointestinal Carcinoid Tumor
• Recurrent Islet Cell Carcinoma
• Recurrent Melanoma
• Recurrent Neuroendocrine Carcinoma of the Skin
• Recurrent Non-small Cell Lung Cancer
• Recurrent Pheochromocytoma
• Recurrent Renal Cell Cancer
• Somatostatinoma
• Stage III Neuroendocrine Carcinoma of the Skin
• Stage IV Melanoma
• Stage IV Non-small Cell Lung Cancer
• Stage IV Renal Cell Cancer
• Thyroid Gland Medullary Carcinoma
• Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

everolimus

Given orally

DRUG

vatalanib

Given orally

OTHER

pharmacological study

Correlative study (Cohort IIA only)

OTHER

laboratory biomarker analysis

Correlative study (Cohorts IIA and IIB)

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Correlative study (Cohort IIA only)

PROCEDURE

ultrasound imaging

Correlative study (Cohorts IIA and IIB)

Sponsors & Collaborators

• Mayo Clinic

  lead OTHER

Principal Investigators

• Julian R. Molina, M.D., Ph.D. · Mayo Clinic

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2004-12-31

Primary Completion

2009-09-15

Completion

2018-01-11

Countries

• United States

Study Locations